---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-007565"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T13:33:48.598092+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Anika Q3 revenue up 25% to $39.5M, net income $0.6M; cuts FY2021 revenue growth outlook to 9-11% from 11-14%

## Summary
- Revenue $39.5M (+25% YoY); Joint Pain Management up 42% to $26.2M.
- Net income $0.6M ($0.04 diluted) vs net loss $6.4M a year ago; adjusted net income $0.8M ($0.05 diluted).
- Adjusted EBITDA $5.8M vs $4.9M; operating cash flow $2.1M; cash $91.0M.
- FY2021 revenue growth guidance revised to 9-11% (previously 11-14%) due to COVID Delta variant headwinds.
- Launched WristMotion Total Wrist Arthroplasty; received 510(k) clearance for Tactoset hardware augmentation.

## SEC filing metadata
- accession: 0001171843-21-007565
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184321007565/0001171843-21-007565-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184321007565/f8k_110421.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-007565
- JSON: https://secwatch.observer/filing/0001171843-21-007565.json
- Plain text: https://secwatch.observer/filing/0001171843-21-007565.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.